Preclinical Ophthalmic Drug Development Services ace

Solid Lipid Nanoparticle Development Services for Ocular Drug Delivery

Solid lipid nanoparticles (SLNs) are critical research vehicles for novel ocular delivery systems. To help global customers face all the challenges and difficulties in developing ocular delivery systems, Ace Therapeutics provides one-stop solid lipid nanoparticle ocular delivery system development services to international customers. In addition, we can customize and develop targeted drug delivery forms according to customers' needs, including nano-eye drops, emulsions, and retinal gene therapy vectors.

Development of a Solid Lipid Nanoparticle Drug Delivery System for Ocular Disease

Advantages of Solid Lipid Nanoparticles for Ocular Delivery Systems

Developing effective ocular drug delivery is a challenge for pharmaceutical scientists due to the complex nature and structure of the eye. Barriers such as the epithelial barrier, blood-water barrier, water-vitreous barrier, and blood-retinal barrier limit drug entry into the eye through different routes. Therefore, there is a need to develop novel drug-delivery vehicles that increase ocular bioavailability and reduce local and systemic cytotoxicity. Solid lipid nanoparticles (SLNs) have been considered as a potential drug delivery system with the properties of not showing biotoxicity, enhancing corneal absorption of drugs, and improving ocular bioavailability of hydrophilic and lipophilic drugs, allowing autoclaving and other advantages. It prolongs the retention time of applied formulations in the ocular epithelium, enhancing corneal penetration through various transport mechanisms. Furthermore, SLNs dispersed in mucoadhesive polymer gel formulations have controlled drug release and prolonged stability.

Fig. 1. Different types of solid lipid nanoparticles and nanostructured lipid carriers. (Gugleva V, et al., 2023)

What Is Ace Therapeutics Doing for Ocular Drug Delivery System Development?

The ocular drug delivery system has been the focus of research and development of ophthalmic drugs in recent years. As a contracting organization for a full range of ocular disease solutions, Ace Therapeutics puts the development of advanced drug delivery systems at the core of its ophthalmic drug development services. We have integrated many well-known ocular delivery system development scholars into our technical system to serve thousands of customers worldwide.

Solid lipid nanoparticles (SLNs) as a potential drug delivery system have attracted researchers worldwide. Here, we provide leading solid lipid nanoparticle ocular delivery system development services. Our talented scientists will develop a custom protocol for your candidate compound.

One-stop Solid Lipid Nanoparticle Drug Delivery System Development Service for Ocular Disease

In order to develop sustained-release ophthalmic drug preparations, Ace Therapeutics uses solid lipid nanoparticle delivery systems. This can prolong drug residence in the eye, control drug release rates, and improve bioavailability. With years of experience and technical level in ocular delivery system research, Ace Therapeutics can provide our customers with one-stop solid lipid nanoparticle ocular delivery system development services. Importantly, our research team can develop the solid lipid nanoparticles you need in different forms. These include nano eye drops, emulsions, gene therapy vectors for eye diseases, etc.

We provide the following services, including but not limited to:

Preparation of solid lipid nanoparticles

High-pressure homogenization and thermal homogenization technology
Cold homogenization technology
Solvent emulsion/evaporation method
High shear homogenization and/or sonication
Microwave-assisted

Characterization of solid lipid nanoparticles

Particle size
Zeta potential
Encapsulation efficiency
Drug loading

In vitro cell evaluation
Corneal permeability assessment
Early ocular pharmacodynamic assessment
Ocular irritation assessment
Live animal models of ocular disease

Application Fields

Age-Related Macular Degeneration (AMD)
Diabetic Retinopathy (DR)
Uveitis
Glaucoma
Retinitis Pigmentosa(RP)

Our Capabilities

Additionally, Ace Therapeutics offers the following other ocular delivery systems that may be of interest to you, ask our scientists for details.

As a contract provider of solutions for ocular diseases, in order to better understand unmet needs, successful delivery of ocular drug delivery systems. Ace Therapeutics can provide our customers with one-stop solid lipid nanoparticle ocular delivery system development services. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Gugleva V, Andonova V. Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms. Pharmaceuticals (Basel). 2023 Mar 22;16(3):474.
Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010 Sep-Oct;17(7):467-89.

For Research Use Only.

Get in Touch